Review scope
Studies selected compared LMWH with placebo or no thromboprophylaxis in adults with a leg injury requiring immobilization in a plaster cast or brace in an ambulatory setting. Outcomes were symptomatic or asymptomatic VTE (deep venous thrombosis [DVT] or pulmonary embolism) and bleeding events.
Review methods
Cochrane Peripheral Vascular Diseases Group Specialized Register, PubMed, and EMBASE/Excerpta Medica (May 2008); Cochrane Central Register of Controlled Trials (Issue 2, 2008); and reference lists were searched for randomized controlled trials (RCTs) and controlled clinical trials. Pharmaceutical companies were consulted. 6 RCTs (n = 1490, mean age 34 to 49 y, 46% to 79% men) met the selection criteria. DVT was diagnosed by venography or by compression ultrasonography and/or duplex scanning confirmed by phlebography or venography. 4 trials reported adequate allocation concealment, 3 placebo-controlled trials were double-blind, and the outcome assessor was blinded in 1 trial.
Main results
Risk for VTE was 18% in the control group. LMWH reduced risk for VTE (symptomatic or identified by screening) and symptomatic VTE (Table) . Treatment effect was similar in patients with a below-knee cast, in operated or nonoperated patients, in patients with fracture or soft-tissue injury, and in patients with distal or proximal segment DVT. Pulmonary embolism was reported in 2 patients (0.4%), both receiving placebo. Major bleeding events were rare, and groups did not differ for minor bleeding events.
Conclusion
In adults with leg immobilization, thromboprophylaxis with low-molecular-weight heparin reduces risk for venous thromboembolism by about half, and risk for bleeding events is low. 
Source of funding: Scottish Government

Commentary
Lower-extremity injuries distal to the knee (fractures, ligament and cartilage injuries of the knee and ankle, and rupture of the Achilles tendon) requiring immobilization in an ambulant setting are common at all ages and increase risk for VTE. Wide practice variations in thromboprophylaxis exist, and not all guidelines recommend prophylaxis because of the scarcity of methodologically adequate trials. Although the American College of Chest Physicians 2008 guidelines do not recommend routine prophylaxis in isolated lower-extremity injuries (1), European guidelines recommend prophylaxis in high-risk patients, for fractures, or when the leg is immobilized or full weight-bearing is not possible (2, 3) .
The review by Testroote and colleagues included 6 RCTs that compared different types of LMWH with placebo or no prophylaxis, with varying results. Concealment of allocation was adequate in only 4 trials, and only 4 trials were either double-blind or had blinded outcome assessment. The authors stated that sensitivity analysis did not change the main results (data not reported). DVT was diagnosed with ultrasonography in 3 trials and with venography in 3 trials, but > 80% of DVT cases were distal, and ultrasonography has lower accuracy than venography in the diagnosis of distal DVT (4).
As noted by the authors, the debate on the use of LMWH in this setting focuses on 2 issues: symptomatic VTE reduction and the clinical relevance of distal DVT, especially when asymptomatic and venographically identified. LMWH reduced symptomatic VTE with a number needed to treat of 49, albeit with a large confidence interval. Proximal DVT ranged from 0% to 4.0% in 614 patients treated with LMWH compared with 0.9% to 6.4% in the control group (odds ratio 0.41, 95% CI 0.19 to 0.91). Heparin-induced thrombocytopenia was not reported in any trial.
Although the results of the meta-analysis by Testroote and colleagues favor LMWH, many questions remain, including the risk-benefit ratio for subgroups of patients. Further methodologically adequate trials are needed to address these concerns.
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